triple negative breast cancer src

Release time ：Dec-21,2024

Triple-negative breast cancer (TNBC) is a distinct subtype of breast cancer, defined by the absence of estrogen receptors, progesterone receptors, and an overabundance of human epidermal growth factor receptor 2 (HER2) on the tumor cell surface. The lack of these receptors makes TNBC less responsive to conventional endocrine therapies and targeted treatments, leading to a reliance on chemotherapy as the primary treatment modality.

Chemotherapy for TNBC includes, but is not limited to, anthracycline and taxane-based regimens. Given the high heterogeneity of TNBC, treatment responses can vary significantly among patients. Consequently, physicians tailor treatment plans to the individual patient's circumstances. Moreover, with advancements in medical research, innovative therapies such as immunotherapy are increasingly being incorporated into the treatment of TNBC, offering patients a broader range of therapeutic options.

For individuals diagnosed with TNBC, it is imperative to seek prompt medical attention and adhere to standardized treatment protocols. Patients should vigilantly monitor their health status throughout the treatment journey and make medication adjustments under the guidance of their healthcare provider. It is crucial not to alter medication dosages or discontinue treatment without professional advice to ensure optimal therapeutic outcomes.